Skip to content

Pretreatment to Reduce Pain and Discomfort During Fiberoptic Nasal Pharyngoscopy and Laryngoscopy

Pretreatment With Topical Anesthesia or Decongestant for Reducing Pain and Discomfort During Fiberoptic Nasal Pharyngoscopy and Laryngoscopy: A Double Blind Randomized Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03620513
Enrollment
160
Registered
2018-08-08
Start date
2018-09-01
Completion date
2019-02-16
Last updated
2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Throat Disorder

Brief summary

Fiberoptic laryngoscopy (FOL) is one of the most common procedure done in an Ear Nose Throat (ENT) clinic. Topical anesthesia or decongestant or both have been used to improve patient comfort level during the procedure. Recently, role of these agents has been questioned. The investigators would like to study whether topical anesthesia or decongestant or their combination provide any benefit to the patients undergoing FOL.

Detailed description

Patient undergoing Fiberoptic laryngoscopy (FOL) will be randomized into four groups by block randomization. Group one will receive atomized spray of normal saline as placebo before the procedure. Group two will receive two sprays of atomized oxymetazoline (approx 0.18 ml of 0.05% oxymetazoline) with a gap of 10 seconds in between the sprays. Group three will receive two sprays of 15% lidocaine with a gap of 10 seconds in between the sprays. Group four will receive two sprays of oxymetazoline and then two sprays of lidocaine at an interval of two minutes. Sample size calculation: With alpha error of 0.05, power of .8, mean discomfort scale for placebo of 2.8 (literature review) and SD of 1.1, presuming that the treatment would be able to reduce discomfort by at least 25%, with two tailed test and same SD, minimum sample size would be 40 in each group. To reduce bias, all the procedure will be performed by senior consultants. Patients and the person performing the procedure will be blinded. Discomfort of pre-medication, discomfort of scope insertion, pain due to scope insertion, and ease of procedure will be scored as VAS score (1 to 10, 1 is least and 10 is most). Also, patient will be asked how likely s/he is to recommend the similar procedure to his/her friends and family members in case they need to undergo the same. Side effects of pre-medication and procedure will also be noted. Outcome variables among the groups will be compared using ANOVA test if they are normally distributed.

Interventions

DRUGDecongestant (oxymetazoline 0.05%)

As described in arm/group

DRUGAnesthesia (Lidocaine 15%)

As described in arm/group

DRUGDecongestants and Anesthesia (oxymetazoline and lidocaine)

As described in arm/group

DRUGNormal saline

Spray of normal saline as premedication

Sponsors

Lumbini Medical College
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Intervention model description

Four arms of study group with equal number of subjects in each group

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing fiberoptic naso pharyngo laryngoscopy in OPD setting * Consent to study * above 18 years

Exclusion criteria

* gross nasal mass * pregnants * known hypersensitivity to the drugs used for premedication * who cannot respond to questionnaire during data collection

Design outcomes

Primary

MeasureTime frameDescription
Discomfort of procedure (fiberoptic nasopharyngolaryngoscopy) as VAS 1-10At the end of the procedureDiscomfort will be scored as VAS on a scale of 1 to 10 (1 is least, 10 is most)

Secondary

MeasureTime frameDescription
Prevalence of adverse effects of pre-medicationfour minutes from the first sprayallergy, burning pain, altered taste, chocking sensation, headache will be asked and recorded
Pain due to procedure as VAS 1-10At the end of the procedurePain will be scored as VAS on a scale of 1 to 10 (1 is least, 10 is most)
Discomfort of pre-treatment as VAS 1-10four minutes from the first sprayDiscomfort will be scored as VAS on a scale of 1 to 10 (1 is least, 10 is most)
Prevalence of adverse effects of procedureAt the end of the procedurebleeding, gag, nausea, vomiting will be noted
Likely to recommend (not likely, can not say, very likely)At the end of the procedurePatient will be asked, How likely you are to recommend this procedure to your relative in case they are advised to. It will be scored as 1-Not at all; 2-not sure; 3-Strongly recommend
Ease of procedure as VAS 1-10At the end of the procedureEase will be scored as VAS on a scale of 1 to 10 (1 is least, 10 is most)

Countries

Nepal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026